Journal of Comparative Effectiveness Research

Papers
(The H4-Index of Journal of Comparative Effectiveness Research is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Journal of Comparative Effectiveness Research : 2022 year in review50
Effect of home-based exercise programs with e-devices on falls among community-dwelling older adults: a meta-analysis48
Long-term effectiveness and safety of ravulizumab in paroxysmal nocturnal hemoglobinuria: a plain language summary38
Ataluren for the treatment of people living with nonsense mutation Duchenne muscular dystrophy: a plain language summary of Study 04136
Access in all areas? A round-up of developments in market access and health technology assessment: part 1031
Economic burden of sickle cell disease in the United States: a retrospective analysis of a commercial insurance database29
Acute effects of resistance exercise with blood flow restriction on cardiovascular response: a meta-analysis29
Engaging veterans in the research process: a practical guide28
Atezolizumab with chemotherapy in first-line treatment for metastatic urothelial cancer: a cost–effectiveness analysis26
Smart connected insulin dose monitoring technologies versus standard of care: a Canadian cost–effectiveness analysis25
MOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapy23
Postoperative outcomes and anesthesia type in total knee arthroplasty in patients with obstructive sleep apnea22
Effectiveness and safety of asfotase alfa for people with hypophosphatasia: a plain language summary of three studies21
Comparative safety of B/F/TAF versus other antiretroviral therapy regimens for treatment-naïve people with HIV-1: a systematic literature review and network meta-analysis21
Impact of surgical complications on hospital costs and revenues: retrospective database study of Medicare claims20
Costs associated with nonalcoholic steatohepatitis disease progression in Medicare patients: a retrospective cohort study18
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 2018
Clinical assessment of the potential use of a novel single-dose prefilled injection device for the administration of Acthar Gel in children: a narrative review17
Bayesian hierarchical model-based network meta-analysis to overcome survival extrapolation challenges caused by data immaturity17
Time-limited reimbursement and Temporary Access Process for early access to oncology treatments in Canada: a perspective based on the epcoritamab experience17
0.060625076293945